AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30719442 — intervention group
Group type: COMPARATOR
Intervention: Balloon group (BG)
Number of subjects: 66
Study 30719442 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study 30385540 — intervention group
Group type: COMPARATOR
Intervention: No saline
Number of subjects: 427
Study 30385540 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.225% saline
Number of subjects: 427
Study 30385540 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline
Number of subjects: 427
Study 26541531 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 72
Study 26541531 — intervention group
Group type: COMPARATOR
Intervention: Sham-CPAP (placebo-controlled)
Number of subjects: 72
Study 26541531 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline (before treatment)
Number of subjects: 72
Study 24809397 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based psychoeducation
Number of subjects: 107
Study 24809397 — intervention group
Group type: COMPARATOR
Intervention: Conventional psychoeducation
Number of subjects: 107
Study 24809397 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 107
Study 22366477 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/STI risk reduction intervention (n = 49)
Number of subjects: 166
Study 22366477 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/STI risk reduction and motivational interviewing (n = 58)
Number of subjects: 166
Study 22366477 — intervention group
Group type: COMPARATOR
Intervention: Wellness promotion (control group, n = 59)
Number of subjects: 166
Study 21137167 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with Urovaxom and Luivac combined with small doses of fluorochinolones over 12 months
Number of subjects: 0
Study 21137167 — intervention group
Group type: COMPARATOR
Intervention: Long-term chemoprophylaxis with small doses of fluorochinolones
Number of subjects: 0
Study 17938729 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E and selenium supplementation
Number of subjects: 115
Study 15226323 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide (150 mg by mouth daily)
Number of subjects: 52
Study 15226323 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide
Number of subjects: 52
Study 15226323 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Number of subjects: 52
Study 11420821 — intervention group
Group type: EXPERIMENTAL
Intervention: No-suction group (n = 154)
Number of subjects: 305
Study 11420821 — intervention group
Group type: COMPARATOR
Intervention: Control group with wound drainage (n = 151)
Number of subjects: 305
Study 10193282 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 20
Study 10193282 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 20
Study 7886332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (12-week program added to ordinary daycare agenda)
Number of subjects: 65
Study 7886332 — intervention group
Group type: COMPARATOR
Intervention: Control group (ordinary daycare agenda)
Number of subjects: 65
Study 7886332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (12-week program)
Number of subjects: 65
Study 3264710 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (600 mg four times daily; 17 doses)
Number of subjects: 20
Study 3264710 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin BP (50 mg three times daily; 13 doses)
Number of subjects: 20
Study 3264710 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocid‐R (75 mg twice daily; 9 doses)
Number of subjects: 20
Study 3264710 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin Continus (75 mg twice daily; 9 doses)
Number of subjects: 20
Study 3264710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31074089 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocurcumin
Number of subjects: 24
Study 31074089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29908436 — intervention group
Group type: COMPARATOR
Intervention: Exposure to zero ACEs
Number of subjects: 1469
Study 29908436 — intervention group
Group type: COMPARATOR
Intervention: Exposure to one ACE
Number of subjects: 1469
Study 29908436 — intervention group
Group type: COMPARATOR
Intervention: Exposure to two ACEs
Number of subjects: 1469
Study 29908436 — intervention group
Group type: COMPARATOR
Intervention: Exposure to three or more ACEs
Number of subjects: 1469
Study 29908436 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEs exposure
Number of subjects: 1469
Study 26515258 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored cutpoint based on an equation combining age, age(2), and 400 m gait speed
Number of subjects: 1448
Study 26515258 — intervention group
Group type: COMPARATOR
Intervention: Standard fixed cutpoints
Number of subjects: 1448
Study 25341154 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA of both viable HCC and retained iodized oil (group A)
Number of subjects: 85
Study 25341154 — intervention group
Group type: COMPARATOR
Intervention: RFA of viable HCC only (group B)
Number of subjects: 85
Study 23514770 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation (MMS) with 5 mg of iron (ferrous sulfate) for 5 months
Number of subjects: 2730
Study 23514770 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2730
Study 20470276 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sucrose (50 mg) with N-acetylcysteine
Number of subjects: 40
Study 20470276 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sucrose (100 mg)
Number of subjects: 40
Study 20470276 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sucrose (50 mg)
Number of subjects: 40
Study 20470276 — intervention group
Group type: COMPARATOR
Intervention: Haemodialysis
Number of subjects: 40
Study 18627279 — intervention group
Group type: EXPERIMENTAL
Intervention: mDOT intervention
Number of subjects: 50
Study 16934143 — intervention group
Group type: EXPERIMENTAL
Intervention: Back care education session followed by the 12-week USC Spine Exercise Program
Number of subjects: 100
Study 16934143 — intervention group
Group type: COMPARATOR
Intervention: One session of back care education
Number of subjects: 100
Study 14736075 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosiplex (Isoprinosine) 100 mg/kg/day to a maximum of 3 g/day, taken orally in three divided doses for 6 months
Number of subjects: 121
Study 14736075 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of inosiplex and intraventricular interferon‐alpha2b (Intron A), starting with 100,000 U/m2 and escalating to 1,000,000 U/m2 over 5 inpatient days, then 1,000,000 U/m2 twice a week for 6 months
Number of subjects: 121
Study 14736075 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 121
Study 14743227 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg atorvastatin
Number of subjects: 10305
Study 14743227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10305
Study 10425809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (25 mg/kg)
Number of subjects: 56
Study 10425809 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 56
Study 7593739 — intervention group
Group type: EXPERIMENTAL
Intervention: Height (continuous)
Number of subjects: 0
Study 7593739 — intervention group
Group type: EXPERIMENTAL
Intervention: Height (continuous) in males
Number of subjects: 0
Study 7593739 — intervention group
Group type: EXPERIMENTAL
Intervention: Height (continuous) in females
Number of subjects: 0
Study 7593739 — intervention group
Group type: EXPERIMENTAL
Intervention: Height (continuous) in untreated males (not randomized to propranolol)
Number of subjects: 0
Study 2272191 — intervention group
Group type: EXPERIMENTAL
Intervention: Cronassial (100 mg in 2 ml buffered solution)
Number of subjects: 25
Study 2272191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 6250769 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of Acyclovir (9‐(2‐hydroxyethoxymethyl)guanine)
Number of subjects: 0
Study 6250769 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 22655911 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + 0.5% AZM
Number of subjects: 63
Study 22655911 — intervention group
Group type: COMPARATOR
Intervention: SRP + placebo gel
Number of subjects: 63
Study 25575254 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-pore polypropylene mesh
Number of subjects: 107
Study 25575254 — intervention group
Group type: COMPARATOR
Intervention: Control (no mesh)
Number of subjects: 107
Study 24075453 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 5 mg
Number of subjects: 551
Study 24075453 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 15 mg
Number of subjects: 551
Study 24075453 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 50 mg
Number of subjects: 551
Study 24075453 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Number of subjects: 551
Study 24075453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study 21860339 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine treatment in patients with different genotypes
Number of subjects: 271
Study 21860339 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine treatment in patients with CYP2B6 516G>T polymorphism
Number of subjects: 271
Study 21860339 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine treatment in patients with CYP2C19 8403AA genotype
Number of subjects: 271
Study 19387646 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate plus TNF alpha antagonist
Number of subjects: 144
Study 19387646 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (15–20 mg weekly for 3 months)
Number of subjects: 144
Study 17426399 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol gum (XYL)
Number of subjects: 127
Study 17426399 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltitol gum (MAL)
Number of subjects: 127
Study 17426399 — intervention group
Group type: COMPARATOR
Intervention: Control group (CR)
Number of subjects: 127
Study 15480990 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant coagulation factor VIIa (rFVIIa) 100 microg/kg, 8 doses
Number of subjects: 245
Study 15480990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 11561267 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with local anesthetics (group B)
Number of subjects: 2
Study 11561267 — intervention group
Group type: COMPARATOR
Intervention: Systemic buprenorphine (group A)
Number of subjects: 2
Study 9645802 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral (cyclosporine microemulsion)
Number of subjects: 466
Study 9645802 — intervention group
Group type: COMPARATOR
Intervention: Sandimmune (traditional cyclosporine)
Number of subjects: 466
Study 9645802 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral
Number of subjects: 466
Study 9645802 — intervention group
Group type: COMPARATOR
Intervention: Sandimmune
Number of subjects: 466
Study 7935146 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational exposure to mercury
Number of subjects: 91
Study 7935146 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exposure to mercury)
Number of subjects: 91
Study 3356847 — intervention group
Group type: EXPERIMENTAL
Intervention: Four different SR theophylline formulations
Number of subjects: 10
Study 30770279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone-beam computed tomographic (CBCT) imaging
Number of subjects: 60
Study 30770279 — intervention group
Group type: EXPERIMENTAL
Intervention: PR, CBCT imaging, and 3D Endo software
Number of subjects: 60
Study 30770279 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiographs (PR) only
Number of subjects: 60
Study 30770279 — intervention group
Group type: EXPERIMENTAL
Intervention: PR and CBCT imaging
Number of subjects: 60
Study 28954098 — intervention group
Group type: EXPERIMENTAL
Intervention: Homologous platelet gel
Number of subjects: 16
Study 28954098 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid dressing
Number of subjects: 16
Study 25902745 — intervention group
Group type: EXPERIMENTAL
Intervention: J-tip guidewire
Number of subjects: 131
Study 25902745 — intervention group
Group type: COMPARATOR
Intervention: Angled-tip guidewire
Number of subjects: 131
Study 23646835 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality reminders
Number of subjects: 0
Study 23646835 — intervention group
Group type: COMPARATOR
Intervention: Control topic
Number of subjects: 0
Study 21333984 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone
Number of subjects: 1373
Study 21333984 — intervention group
Group type: COMPARATOR
Intervention: Micronized vaginal P gel
Number of subjects: 1373
Study 21333984 — intervention group
Group type: COMPARATOR
Intervention: Micronized P capsule
Number of subjects: 1373
Study 19250079 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-PM
Number of subjects: 233
Study 19250079 — intervention group
Group type: COMPARATOR
Intervention: CRT-D
Number of subjects: 233
Study 17499653 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine and epinephrine (TLE) using sequential layered application
Number of subjects: 100
Study 17499653 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine infiltration anesthesia (Control)
Number of subjects: 100
Study 17499653 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine and epinephrine (TLE)
Number of subjects: 100
Study 15201857 — intervention group
Group type: EXPERIMENTAL
Intervention: Infasurf
Number of subjects: 40
Study 15201857 — intervention group
Group type: COMPARATOR
Intervention: Survanta
Number of subjects: 40
Study 15201857 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Infasurf and Survanta
Number of subjects: 40
Study 12585303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical pricing after the policy change regarding patient out-of-pocket expenses.
Number of subjects: 0
Study 12585303 — intervention group
Group type: EXPERIMENTAL
Intervention: Branded products facing generic competitors.
Number of subjects: 0
Study 9706049 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum-based diltiazem formulations
Number of subjects: 8
Study 9706049 — intervention group
Group type: COMPARATOR
Intervention: Dilacor XR
Number of subjects: 8
Study 7699350 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental patient education materials (office-based videos, pamphlets, and posters)
Number of subjects: 770
Study 7699350 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational materials)
Number of subjects: 770
Study 2712549 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day amantadine
Number of subjects: 554
Study 2712549 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day amantadine
Number of subjects: 554
Study 2712549 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/day amantadine
Number of subjects: 554
Study 2712549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 554
Study 325650 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 to 10 milligrams)
Number of subjects: 19
Study 325650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 325650 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 19
Study 31874181 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (5 hours)
Number of subjects: 20
Study 31874181 — intervention group
Group type: COMPARATOR
Intervention: Sleep fragmentation (light on every hour)
Number of subjects: 20
Study 31225666 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTIONS (decision support intervention)
Number of subjects: 37
Study 31225666 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 37
Study 29188864 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein intake (1.3 g/kg/day)
Number of subjects: 92
Study 29188864 — intervention group
Group type: COMPARATOR
Intervention: Lower protein intake (0.8 g/kg/day)
Number of subjects: 92
Study 29188864 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (vs. placebo)
Number of subjects: 92
Study 29188864 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vs. testosterone)
Number of subjects: 92
Study 25967892 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced nutrient supply (increased energy, protein, fat, essential fatty acids, and vitamin A)
Number of subjects: 50
Study 25967892 — intervention group
Group type: COMPARATOR
Intervention: Standard nutritional care (control group)
Number of subjects: 50
Study 23488545 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine (30 nmol min(‐1))
Number of subjects: 0
Study 23488545 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-receptor antagonists
Number of subjects: 0
Study 23488545 — intervention group
Group type: COMPARATOR
Intervention: H1-receptor antagonists
Number of subjects: 0
Study 23488545 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 0
Study 22123796 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine therapy sampling
Number of subjects: 849
Study 22123796 — intervention group
Group type: COMPARATOR
Intervention: PQA intervention
Number of subjects: 849
Study 19619700 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline use of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB)
Number of subjects: 16588
Study 19619700 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with early VF/VT on baseline ACEI/ARB
Number of subjects: 16588
Study 19619700 — intervention group
Group type: COMPARATOR
Intervention: Patients without early VF/VT
Number of subjects: 16588
Study 19619700 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with early VF/VT
Number of subjects: 16588
Study 16969070 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib (BAY 43-9006)
Number of subjects: 0
Study 16969070 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 15231001 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural counselling
Number of subjects: 271
Study 15231001 — intervention group
Group type: COMPARATOR
Intervention: Nutritional education counselling
Number of subjects: 271
Study 11128341 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10-20 mg once a day)
Number of subjects: 48
Study 11128341 — intervention group
Group type: COMPARATOR
Intervention: Nisoldipine (20-40 mg once a day)
Number of subjects: 48
Study 9371877 — intervention group
Group type: EXPERIMENTAL
Intervention: [123I]FE-CIT
Number of subjects: 6
Study 9371877 — intervention group
Group type: EXPERIMENTAL
Intervention: [123I]FP-CIT
Number of subjects: 6
Study 8104107 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SFA‐‐cholesterol (LSC) diet for 5 weeks
Number of subjects: 37
Study 8104107 — intervention group
Group type: EXPERIMENTAL
Intervention: High SFA‐‐cholesterol (HSC) diet for 5 weeks
Number of subjects: 37
Study 3522031 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 285
Study 3522031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 30345611 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of ranibizumab + pro re nata (prn)
Number of subjects: 50
Study 30345611 — intervention group
Group type: COMPARATOR
Intervention: 3 doses of ranibizumab + pro re nata (prn)
Number of subjects: 50
Study 28691269 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus followed by 2 mg/kg/hour infusion)
Number of subjects: 148
Study 28691269 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (same bolus and infusion rate as lidocaine)
Number of subjects: 148
Study 28691269 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 148
Study 28691269 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 148
Study 27317550 — intervention group
Group type: EXPERIMENTAL
Intervention: Ametop™ (tetracaine 4%) gel applied to the skin of the lower back at least 20min before neuraxial block
Number of subjects: 72
Study 27317550 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied to the skin of the lower back at least 20min before neuraxial block
Number of subjects: 72
Study 25157013 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted controlled intervention
Number of subjects: 32
Study 25157013 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall composite measure
Number of subjects: 32
Study 25157013 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 21971356 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titer neutralizing antibodies (NAb) against two or more isolates (90% inhibitory dose > 500)
Number of subjects: 50
Study 19857447 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 μg IXIARO®
Number of subjects: 60
Study 19857447 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 μg IXIARO®
Number of subjects: 60
Study 19857447 — intervention group
Group type: COMPARATOR
Intervention: JenceVac™
Number of subjects: 60
Study 17977528 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment
Number of subjects: 31
Study 17977528 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged abstinence
Number of subjects: 31
Study 15095213 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin, 500 mg per week for 8 weeks (R1)
Number of subjects: 1683
Study 15095213 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin, 1500 mg once at enrollment (R2)
Number of subjects: 1683
Study 15095213 — intervention group
Group type: COMPARATOR
Intervention: No therapy (R3)
Number of subjects: 1683
Study 11806304 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 antihistamines
Number of subjects: 0
Study 9551842 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (10 mg three-times daily)
Number of subjects: 154
Study 7998046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 294
Study 7998046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study 3051945 — intervention group
Group type: EXPERIMENTAL
Intervention: CG-120 (3 or 4 g daily)
Number of subjects: 398